Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 12.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1999 to 2008

Recipients with Lung Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 922 977 1,083 1,054 1,099 1,185 1,407 1,406 1,471 1,478
Tx with Antirejection Treatments 396 432 500 425 358 384 435 388 383 390
Antibodies Any in Category 16.4% 18.8% 11.2% 13.4% 16.2% 13.8% 12.4% 12.9% 14.4% 14.1%
Atgam/NRATG/NRATS 8.3% 7.4% 4.2% 3.1% 4.7% 4.2% 4.1% 7.0% 4.7% 4.4%
OKT3 3.0% 2.5% 1.4% 1.9% 0.8% 1.0% 0.9% 0.3% 1.3% 0.0%
Thymoglobulin 5.1% 5.8% 5.8% 4.9% 5.6% 6.8% 6.7% 5.4% 6.3% 8.2%
Zenapax 1.0% 3.0% 0.8% 5.2% 7.0% 1.8% 0.5% 0.0% 0.3% 0.3%
Simulect 0.8% 2.8% 0.6% 0.2% 0.6% 0.5% 1.1% 0.3% 1.8% 0.8%
Campath 0.0% 0.0% 0.0% 0.5% 0.8% 0.5% 0.5% 0.0% 0.5% 1.3%
Corticosteroids Any in Category 93.2% 88.2% 92.6% 95.1% 96.1% 93.8% 94.9% 91.2% 93.5% 93.8%
Steroids 93.2% 88.2% 92.6% 95.1% 96.1% 93.8% 94.9% 91.2% 93.5% 93.8%
Antimetabolites Any in Category 1.5% 1.2% 1.2% 0.2% 1.4% 0.5% 1.1% 1.3% 1.0% 1.0%
Cytoxan 0.8% 0.5% 0.2% 0.2% 0.6% 0.5% 0.5% 1.3% 0.5% 0.8%
Methotrexate 1.5% 0.7% 1.0% 0.0% 0.8% 0.0% 0.7% 0.0% 0.5% 0.3%


Source: OPTN/SRTR Data as of October 1, 2010.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.